87 Ces Urol 2024; 28(2): 69–88 PŘEHLEDOVÉ ČLÁNKY 28. Rubin MA, Kleter B, Zhou M, et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol. 2001; 159: 1211–1218. 29. Gunia S, Erbersdobler A, Hakenberg OW, et al. p16(INK4a) is a marker of good prognosis for primary invasive penile squamous cell carcinoma: a multi-institutional study. J Urol. 2012; 187(3): 899–907. 30. Ferrándiz-Pulido C, Masferrer E, de Torres I, et al. Identification and genotyping of human papillo‑ mavirus in a Spanish cohort of penile squamous cell carcinomas: correlation with pathologic subtypes, p16(INK4a) expression, and prognosis. J Am Acad Dermatol. 2013; 68(1): 73–82. 31. Steinestel J, Al Ghazal A, Arndt A, et al. The role of histologic subtype, p16(INK4a) expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma. BMC Cancer. 2015; 15: 220. 32. Tang DH, Clark PE, Giannico G, et al. Lack of P16ink4a over expression in penile squamous cell carci‑ noma is associated with recurrence after lymph node dissection. J Urol. 2015; 193(2): 519–525. 33. Ueno H, Murphy J, Jass JR, et al. Tumour ‚budding‘ as an index to estimate the potential of aggressi‑ veness in rectal cancer. Histopathology. 2002; 40(2): 127–132. 34. Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017; 30(9): 1299–1311. 35. Derani H, Becker AS, Hakenberg O, Erbersdobler A. Evaluation of the cellular dissociation grading, based on tumour budding and cell nest size, in squamous cell carcinoma of the penis. Cancers (Basel). 2022; 14: 4949. 36. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357(9255): 539–545. 37. Pagès F, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010; 29(8): 1093–1102. 38. Liu Y, Liu Z, Yang Y, et al. The prognostic and biology of tumour-infiltrating lymphocytes in the im‑ munotherapy of cancer. Br J Cancer. 2023; 129(7): 1041–1049. 39. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ‚Immunoscore‘ in the classification of malignant tumours. J Pathol. 2014; 232(2): 199–209. 40. Ottenhof SR, Djajadiningrat RS, Thygesen HH, et al. The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma. Front Immunol. 2018; 9: 1253. 41. Clark WH Jr, Elder DE, Guerry D 4th, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81(24): 1893–1904. 42. Yervoy FDA approval history. (citované 08. 03. 2024). Available from: https://www.drugs.com/history/ yervoy.html. 43. Hrudka J, Hojný J, Prouzová Z, et al. High tumour mutational burden is associated with strong PD-L1 expression, HPV negativity, and worse survival in penile squamous cell carcinoma: an analysis of 165 cases. Pathology. 2024; 56(3): 357–366. 44. Kopecký J. Potenciální checkpoint inhibitory využitelné v léčbě nádorů. Onkologie. 2022; 16(3): 115–117. 45. Elst L, Philips G, Vandermaesen K, et al. Single-cell Atlas of Penile Cancer Reveals TP53 Mutations as a Driver of an Aggressive Phenotype, Irrespective of Human Papillomavirus Status, and Provides Clues for Tre‑ atment Personalization. Eur Urol. 2024; Apr 25: S0302–2838(24)02266–8. Epub ahead of print. PMID: 38670879. 46. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969; 71(4): 747–752. 47. Parrales A, Iwakuma T. Targeting Oncogenic Mutant p53 for Cancer Therapy. Front Oncol. 2015; 5: 288. 48. Prapiska FF, Warli SM. P53 and survival rate in penile cancer. Open Access Maced J Med Sci. 2019; 7: 1170–1173. 49. Gunia S, Kakies C, Erbersdobler A, et al. Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis. J Clin Pathol. 2012; 65: 232–236.
RkJQdWJsaXNoZXIy NDA4Mjc=